Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ManpowerGroup (MAN)

ManpowerGroup adds Lidia Fonseca, former Pfizer technology chief, to its board

Neutral Impact 2 of 5 leadership

ManpowerGroup appointed Lidia Fonseca to its Board of Directors, effective November 1, 2026, increasing the board from twelve to thirteen directors. She previously served as Chief Digital and Technology Officer and Executive Vice President at Pfizer, and she has not been named to any board committee, so shareholders should note the appointment as a board composition change rather than an operating event.

Key points

  • Appointed October 26, 2026; service begins November 1, 2026; board size rises from twelve to thirteen.
  • Previously Chief Digital and Technology Officer and Executive Vice President at Pfizer, January 2019 to April 2026; currently Senior Advisor to Pfizer's CEO.
  • As a non-employee director, receives a $120,000 annual cash retainer and an annual deferred stock grant with a fair value of about $180,000, prorated for 2026.
  • Not appointed to any committee of the board; will enter the company's standard director indemnification agreement.

The filing

CompanyManpowerGroup (MAN)
Form8-K, current report
Filed with the SECOct 28, 2026, 1:00 PM ET
Accession number0001193125-26-435727

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.